🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Relaxo 25, also known as Dantrolene, is a medication used to control spasticity resulting from upper motor neuronal disorders such as stroke, spinal cord injury, cerebral palsy, or multiple sclerosis. It can also prevent malignant hyperthermia during surgery. However, Relaxo 25 should be used with caution as it can cause liver damage and is not effective in treating skeletal muscle spasms resulting from rheumatic disorders. Liver function tests should be done before therapy and at intervals during treatment, and patients should avoid driving or hazardous activities while taking them.
No information was found.
Please consult your doctor before taking Relaxo 25 during pregnancy.
Relaxo 25 should not be used by nursing mothers. Please consult your doctor before taking Relaxo 25.
No information was found.
No information was found.
Relaxo 25 may cause liver damage. Before taking Relaxo 25, consult your doctor.
The most frequently occurring side effects of Relaxo 25 have been drowsiness,
Take Relaxo 25 according to your doctor's instructions.
Relaxo 25 is used to control clinical spasticity resulting from upper motor neuronal disorders, such as stroke, spinal cord injury, cerebral palsy, or multiple sclerosis. It may improve residual function in patients with presumably reversible spasticity. Long-term use of Dantrolene is justified if it reduces painful or disabling spasticity, decreases required nursing care, or relieves bothersome spasticity symptoms. Dantrolene can also be given orally to prevent malignant hyperthermia in known or suspected susceptible patients undergoing surgery. After a malignant hyperthermic crisis, Dantrolene can be administered orally to prevent the recurrence of symptoms. It is not effective in treating skeletal muscle spasms resulting from rheumatic disorders.
Dantrolene induces skeletal muscle relaxation by directly affecting the muscle's contractile response beyond the myoneural junction. It likely disrupts the release of calcium from the sarcoplasmic reticulum, leading to the dissociation of excitation-contraction coupling in skeletal muscle.
For Use in Chronic Spasticity:
Adults:
The following gradual titration schedule is suggested. Some patients will not respond until the higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, the dosage should be decreased to the previous lower dose.
Pediatric Patients:
The following gradual titration schedule is suggested. Some patients will not respond until the higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, the dosage should be decreased to the previous lower dose.
For Malignant Hyperthermia:
Drowsiness may occur with Dantrolene therapy, and the concomitant administration of CNS depressants such as sedatives and tranquilizing agents may result in further drowsiness. Hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy.
Active hepatic disease, such as hepatitis and cirrhosis.
Pregnancy Category C. Dantrolene capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dantrolene should not be used in nursing mothers
Relaxo 25 may cause liver damage, so therapy should be stopped if no benefit is seen within 45 days. Patients should avoid driving or hazardous activities while taking it. Liver function tests should be done before starting therapy and at intervals during treatment. If symptoms of liver disease occur, Dantrolene should be discontinued. Caution is needed in the concomitant use of tranquilizers and in patients with liver or lung problems. Females and those over 35 years old are at higher risk for liver disease with Dantrolene use.
Store in a cool & dry place, protected from light.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.